Cemiplimab manufacturers and R&D companies

Cemiplimab (Cemiplimab) was developed by the American company Regeneron Pharmaceuticals and was jointly developed with the French pharmaceutical giant Sanofi. This cooperation model combines Regeneron's technical advantages in antibody drug research and development with Sanofi's extensive global marketing and sales channels, allowing cimepilimab to quickly enter the international market.

Regeneron is a biotechnology company focused on the research and development of antibody drugs. With its proprietaryVelocImmune platform, Regeneron has strong capabilities in the field of antibody research and development. Cimepilimab is one of its important immuno-oncology products. Sanofi, as the world's leading multinational pharmaceutical company, is responsible for the commercialization of this drug in Europe and other international markets. The cooperation between the two has enabled the rapid advancement of cimepilimab in the approval of both the FDA and EMA.

Cimepilimab was first approved by the US FDA in 2018. It is mainly used to treat locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC). Later, it was expanded to non-small cell lung cancer (NSCLC) and other indications. The European Medicines Agency (EMA) also approved its marketing in the same year, and it has become an important member of the field of PD-1 inhibitors in many European and American countries.

Since this variety has not yet obtained marketing authorization in mainland China, the local MAH information and official instruction manual version in the relevant national drug administration database cannot be queried for the time being. If patients obtain the "US version or European version of the original drug" through overseas channels, they should pay attention to the compliance of the source, batch number and expiration date, and avoid informal channels with unknown sources. Generally speaking, "Cimeplimab manufacturers and R&D companies" can be summarized as a global innovative drug paradigm led by Regeneron and coordinated by Sanofi. Its platform capabilities, industrialization capabilities and compliant supply chain jointly support the stable accessibility of drugs in the international market.

Reference materials:https://www.libtayohcp.com/